Adaptive Biotechnologies (ADPT) reported its Q4 loss narrowed to $0.23 a share from the loss of $0.48 a year earlier.
Three analysts polled by FactSet expected a loss of $0.26.
Revenue in the three months ended Dec. 31 rose to $47.5 million from $45.8 million a year earlier, the company said Tuesday in a statement.
Analysts surveyed by FactSet expected $46 million.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。